eculizumab aHUS
Selected indexed studies
- Eculizumab and aHUS: to stop or not. (Blood, 2021) [PMID:33956069]
- Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. (Blood, 2021) [PMID:33270832]
- Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. (Ther Apher Dial, 2019) [PMID:30294946]
_Worker-drafted node — pending editorial review._
Connections
eculizumab aHUS is a side effect of
Sources
- Eculizumab and aHUS: to stop or not. (2021) pubmed
- Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. (2021) pubmed
- Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. (2019) pubmed
- Management of pediatric hemolytic uremic syndrome. (2024) pubmed
- Transplantation in pediatric aHUS within the era of eculizumab therapy. (2021) pubmed
- New findings in preventing recurrence and improving renal function in AHUS patients after renal transplantation treated with eculizumab: a systemic review and meta-analyses. (2023) pubmed
- Complement system activation: bridging physiology, pathophysiology, and therapy. (2024) pubmed
- Eculizumab hepatotoxicity in pediatric aHUS. (2015) pubmed
- Can eculizumab be discontinued in aHUS?: Case report and review of the literature. (2016) pubmed
- Kidney Transplantation in Patients With aHUS: A Comparison of Eculizumab Prophylaxis Versus Rescue Therapy. (2025) pubmed